our findings support acupuncture as an effective treatment in alleviating pain among cancer patients and survivors, particularly malignancy-related and surgery-induced pain. To expand the application of acupuncture on cancer-related pain, investigators should clearly define the types of cancer pain (e.g. malignancy related pain) as inclusion criteria in the future studies.
Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer
We conclude, from this small retrospective study, that TCM treatment was associated with a survival benefit in patients with pancreatic cancer. In addition, TCM in combination with WM would be a better optimal treatment for patients with pancreatic cancer to improve survival time. More importantly, we provide TCM practitioners with a proposal that heat-clearing, diuresis-promoting and detoxification TCM treatment may improve the efficacy of TCM in patients with pancreatic cancer.
More than 50 TCM formulas have been used to treat hyperlipidemia. These herbs can primarily be grouped into three categories: (1) herbs promoting excretions, generally by reducing food retention, enhancing purgative effects, and promoting diuresis and choleretic effects, e.g., Fructus Crataegi (), Radix Polygoni Multiflori (), Semen Cassiae (), and Radix et Rhizoma Rhei (), Rhizoma alismatis (), and Herba Artemisiae Scopariae (); (2) herbs acting on the cardiovascular system, generally by improving blood circulation based on TCM theories, e.g., Radix Salviae Miltiorrhizae (), Radix Puerariae (), Rhizoma Chuanxiong (), Flos Carthami (), and Folium Nelumbinis (); and (3) herbs that have tonic effects, e.g., Fructus Lycii (), Radix Ginseng (), and Radix Astragali ().
Three basic approaches, including excretory function enhancement, cardiovascular system improvement, and tonic effect reinforcement, are emerging among TCM formulas for the treatment of hyperlipidemia. These approaches may be useful in controlling blood lipid levels, preventing cardiovascular complications, and adjusting bodily functions in hyperlipidemic patients. However, solid evidence of the efficacy of these treatments is required.
“Acupuncture Therapies and Neuroplasticity” is an annual special issue published in “Neural Plasticity.” You can find many scientific studies in this journal provided at:
Medical acupuncture is based on physiology and neuroscience like this. From those studies, you can learn how acupuncture works.
Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan
The CHM group was characterized by a longer follow up time and more cases of hyperlipidemia and liver cirrhosis. This group exhibited a lower mortality hazard ratio (0.48, 95% confidence interval [0.39–0.61], p < 0.001), after adjusting for comorbidities. The trend was also observed that the cumulative survival probability was higher in CHM than in non-CHM users (p < 0.0001, log rank test). Analysis of their CHM prescription pattern revealed that Bu-Zhong-Yi-Qi-Tang (BZYQT), Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT), and Bai-He-Gu-Jin-Tang (BHGJT); and Bei-Mu (BM), Xing-Ren (XR) and Ge-Gen (GG) were found to be the top three formulas and herbs, respectively. Among them, BM was the core CHM of the major cluster, and Jie-Geng (JG) and Mai-Men-Dong-Tang (MMDT) were important CHMs by CHM network analysis.
The use of CHM as an adjunctive therapy may reduce the mortality hazard ratio of lung cancer patients.
Effect of rikkunshi-to treatment on chemotherapy-induced appetite loss in patients with lung cancer: A prospective study
In patients treated with CBDCA-containing chemotherapy, food intake at day 7 following the initiation of chemotherapy in the rikkunshi-to treatment group was significantly higher compared with the group not treated with rikkunshi-to (P=0.0078).
“Electro-acupuncture combined with conventional routine care has the potential of reducing spasticity in upper and lower limb and improving overall and lower extremity motor function and activity of daily living for spasticity patients within 180 days post stroke.”
In total, 22 trials met the search criteria and were included involving 1,425 participants. The estimated add-on effects of EA to reduce spasticity in upper limb measured by MAS (SMD: -0.57[-0.84, -0.29]) and improve overall motor function measured by FMA (MD: 10.60[8.67, 12.53]) were significant. It was also found that for spasticity in lower limb, lower-limb motor function and activity of daily living, significant add-on effects of EA were also shown (SMD: -0.88[-1.42, -0.35], MD:4.42[0.06, 8.78] and MD: 6.85[3.64, 10.05] respectively), though with high heterogeneity. For upper-limb motor function, no significant add-on effects of EA was received.